knowledge -WSS

knowledge

author：fashion 2025-10-02 00:41:36 - browse：94

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： What a koala virus tells us about the human genome

WSS

Liz Cheney makes 1st public comment since Trump's election interference indictments

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

WuXi Biologics execs register to lobby as Congress comes for the company

Hilary expected to bring catastrophic, life

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

ProMED sees offers of support, but its future remains unclear

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

WuXi Biologics execs register to lobby as Congress comes for the company

ChatGPT in medicine: STAT answers readers' burning questions

Beware the threat of staffing cuts at the CDC

As demand for Covid shots wanes, Moderna seeks its next success

Cherokee Nation medical school graduates its first class

Medical records are filled with copy

Cherokee Nation medical school graduates its first class

Bright Health sells Medicare Advantage business to Molina

WuXi Biologics execs register to lobby as Congress comes for the company

entertainment

Obesity drug from Roche shows promise in early study

Cancer drug shortages' outsize impact on ovarian cancer patients

Lilly’s weekly insulin works as well as daily products, new studies show

STAT reporters are Pulitzer Prize finalists for investigative reporting

STAT reporters are Pulitzer Prize finalists for investigative reporting

The pain doctors face in trying to build their families

hotspot

knowledge

hotspot

leisure time